Epidemiology and Economic Burden of Diagnosed Congenital Cytomegalovirus Infection in the First 2 Years of Life among Commercially Insured and Medicaid-Insured Individuals in the United States
Diagnosed prevalence of cCMV at birth increased over time from 2010 to 2018. Infants with clinically diagnosed cCMV have costlier birth admissions and substantial disease burden in the first 2 years of life. These results emphasize the need for primary prevention methods, such as vaccination, to decrease the burden of cCMV.
Authors
- Philip O. Buck (ORCID: https://orcid.org/0000-0002-3898-3669)
- John Diaz‐Decaro (ORCID: https://orcid.org/0000-0001-6487-2113)
- Katherine Gaburo (ORCID: https://orcid.org/0000-0003-2197-5029)
- Urvi Desai (ORCID: https://orcid.org/0000-0001-5196-7201)
- Noam Y. Kirson (ORCID: https://orcid.org/0000-0001-5200-6883)
- Gail J. Demmler‐Harrison
- Annika Anderson (ORCID: https://orcid.org/0000-0001-6319-9959)
- Jessica R. Marden (ORCID: https://orcid.org/0000-0001-9108-8711)
- Sandeep Basnet (ORCID: https://orcid.org/0009-0002-4955-930X)
Institutions
- Baylor College of Medicine (US)
- Moderna Therapeutics (United States) (US)
- Texas Children's Hospital (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Clinical Therapeutics
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1016/j.clinthera.2025.03.006
- Citations
- 4
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Moderna